Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a strategic alliance with Technoclone, a reagent specialist in thrombosis and cardiovascular diagnostics based in Vienna, Austria. The alliance complements Roche’s strategic re-focus on hemostasis. Following the discontinuation of the distribution agreement with STAGO1 and the recent acquisition of Verum Diagnostica2, Roche will bring to market a brand-new, innovative hemostasis portfolio including two new system families, platelet function testing and a new holistic reagent offering in 2012.
“With the strategic alliance with Technoclone, Roche continues the revaluation of its coagulation business by expanding its reagent portfolio. Based on Technoclone’s considerable industry expertise and many years of experience, combined with its proximity to the scientific community, the company fully embraces our goal of bringing improved medical value to the patient. This includes joint engagements in clinical research and future reagent developments as novel diagnostic techniques become integral factors in the targeted treatment options of tomorrow”, states Colin Brown, Head of Roche Professional Diagnostics.
Technoclone – founded in 1987 and based in Vienna, Austria – provides a full hemostasis testing portfolio as well as protein and lipid diagnostics. With the acquisition of the former immuno diagnostics division of Baxter in 1998, Technoclone expanded to an international company with an established global distribution system. The company holds more than ten international patents in the diagnosis and therapy of vascular diseases and cooperates closely with universities and international research consortia.
“Given Roche’s unique global position as the market leader in in-vitro diagnostics our alliance will drive further developments in reagents on Roche’s novel platforms, which respond perfectly to customer needs. We are very pleased to ally with Roche as part of their new, holistic vision in hemostasis and believe that our partnership shows a real win-win situation for health professionals and patients worldwide”, states Veronika Binder, CEO of Technoclone.
As part of the strategic alliance, Roche and Technoclone are co-developing a complete range of coagulation reagents that will be part of the menu of assays offered by the two new cobas system families for coagulation diagnostics Roche will introduce starting in 2012: The cobas t 411 and the cobas t 611 analyzers are specially designed to meet the requirements of low to high throughput testing in today’s hemostasis laboratories. From 2014 on, these platforms will be joined by a second system family with three groundbreaking platforms for all customer segments, including the highest throughput customers, with a complete menu of coagulation. Additionally, Roche will market Technoclone’s range of research and specialty use products in selected markets addressing the needs of specialists and researchers in the hemostasis research community.
As global trends show an increased demand for routine and special testing while laboratories are consolidating, centralizing and automating processes in response to cost pressures, the annual growth rate of coagulation diagnostics is projected to exceed 5% in the next five years, with a global market size of over 1.3 billion USD in 2010. Ageing population, rising healthcare costs, advances in science and the many unmet medical needs in the field of hemostasis fuel the need for improved patient outcomes. The strategic alliance with Technoclone will continue to shape Roche’s unique position in the delivery of customized solutions to meet the clinical and laboratory needs of today and tomorrow.
Founded in 1987, Technoclone is a leading global producer of hemostasis diagnostic products. The company was the first worldwide to offer a complete set of monoclonal antibody-based ELISAs in the field of fibrinolysis and a novel patented system allowing the determination of activity and antigen in the same sample. The company holds more than ten international patents in the diagnosis and therapy of vascular diseases and cooperates closely with universities and international research consortia. For more information visit: www.technoclone.com
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche’s personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80’000 employees worldwide and invested over 9 billion Swiss francs in R&D. The Group posted sales of 47.5 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.
All trademarks used or mentioned in this release are protected by law.
1) See Roche’s press release Roche Redefines Global Coagulation Diagnostics from October 4, 2011, http://www.cobas.com/News/Pages/GlobalCoagulationDiagnostics.aspx
2) See Roche’s press release Roche acquires Verum Diagnostica GmbH to strengthen portfolio in coagulation diagnostics from December 2, 2011, http://www.cobas.com/News/Pages/RocheacquiresVerumDiagnosticaGmbH.aspx